Angioscopic Evaluation of Vascular Response After Fluoropolymer-Based Drug-Eluting Stent Implantation for Femoropopliteal Artery Lesions.

BACKGROUND Although favorable clinical outcomes have been demonstrated for fluoropolymer-based paclitaxel-eluting stents (FP-DES) in the treatment of femoropopliteal lesions, the vascular response after implantation has not been systematically studied through intravascular imaging.Methods and Results: We angioscopically compared FP-DES: 24 in the early phase (mean [±SD] 3±1 months), 26 in the middle phase (12±3 months), and 20 in the late phase (≥18 months) after implantation. The dominant neointimal coverage grade, heterogeneity of neointimal coverage grade, and thrombus adhesion in the stent segment were evaluated. Neointimal coverage was graded as follows: Grade 0, stent struts exposed; Grade 1, struts bulging into the lumen, although covered; Grade 2, struts embedded in the neointima, but visible; Grade 3, struts fully embedded and invisible. Dominant neointimal coverage and heterogeneity grades were significantly higher in the middle and late phases than in the early phase (all P<0.05), but did not differ significantly between the middle and late phases. The incidence of thrombus adhesion was recorded for all stents in each of the 3 different phases. CONCLUSIONS The middle and late phases after FP-DES implantation were associated with significantly higher dominant neointimal coverage and heterogeneity grades than the early phase. However, thrombus adhesion was observed in all phases after FP-DES implantation. Arterial healing may not be completed even in the late phase after FP-DES implantation.

[1]  K. Kichikawa,et al.  Clinical expert consensus document on standards for lower extremity artery disease of imaging modality from the Japan Endovascular Treatment Conference , 2022, Cardiovascular Intervention and Therapeutics.

[2]  M. Fujihara,et al.  1-Year Outcomes of Fluoropolymer-Based Drug-Eluting Stent in Femoropopliteal Practice: Predictors of Restenosis and Aneurysmal Degeneration. , 2022, JACC. Cardiovascular interventions.

[3]  T. Bisdas,et al.  2-Year Outcomes of the Eluvia Drug-Eluting Stent for the Treatment of Complex Femoropopliteal Lesions. , 2021, JACC. Cardiovascular interventions.

[4]  R. Virmani,et al.  Vascular Response of a Polymer-free, Paclitaxel-coated Stent (Zilver PTX®) Versus a Polymer-coated, Paclitaxel-eluting Stent (Eluvia®) in Healthy Swine Femoropopliteal Arteries. , 2021, Journal of vascular and interventional radiology : JVIR.

[5]  W. Gray,et al.  Two-Year Efficacy and Safety Results from the IMPERIAL Randomized Study of the Eluvia Polymer-Coated Drug-Eluting Stent and the Zilver PTX Polymer-free Drug-Coated Stent , 2020, CardioVascular and Interventional Radiology.

[6]  R. Virmani,et al.  Vascular responses to coronary calcification following implantation of newer-generation drug-eluting stents in humans: impact on healing. , 2019, European heart journal.

[7]  S. Saito,et al.  Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. , 2016, Journal of cardiology.

[8]  M Hassan Murad,et al.  Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. , 2015, Journal of vascular surgery.

[9]  Takaharu Nakayoshi,et al.  Coronary endothelial dysfunction distal to stent of first-generation drug-eluting stents. , 2012, JACC. Cardiovascular interventions.

[10]  R. Virmani,et al.  Differential healing responses in polymer- and nonpolymer-based sirolimus-eluting stents. , 2008, JACC. Cardiovascular interventions.

[11]  M. Fromm,et al.  Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. , 2008, Journal of the American College of Cardiology.

[12]  M. Takano,et al.  Morphologic changes in infarct-related plaque after coronary stent placement: a serial angioscopy study. , 2003, Journal of the American College of Cardiology.

[13]  R. Virmani,et al.  Pathological Analysis of Local Delivery of Paclitaxel Via a Polymer-Coated Stent , 2001, Circulation.

[14]  E. Ritz,et al.  Dialysis membranes and coagulation system. , 1986, Blood purification.

[15]  A Ross Naylor,et al.  2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed b , 2018, European heart journal.

[16]  L. Fleisher,et al.  2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2017, Journal of the American College of Cardiology.

[17]  S. Nanto,et al.  Extensive arterial repair one year after paclitaxel-coated nitinol drug-eluting stent vs. bare-metal stent implantation in the superficial femoral artery , 2014, Cardiovascular Intervention and Therapeutics.

[18]  M. Aviram,et al.  Enhanced in vitro platelet aggregation in hemodialysis patients. , 1986, Nephron.